GlassScriptPhysician profile
Pankaj M Khemka
NPI 1295826790
$12,264.93
in general payments reported to CMS, 2019-2025
30 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $748 · 2021: $1,261 · 2022: $6,723 · 2023: $1,160 · 2024: $884 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.35 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $6,105.77 | 2019-2023 | Arikayce |
| Gilead Sciences, INC. | $2,099.19 | 2019-2025 | Yeztugo, Biktarvy |
| Viiv Healthcare Company | $1,240.50 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Pharmaceuticals, INC | $423.80 | 2019-2023 | |
| Astellas Pharma US INC | $423.22 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $353.99 | 2019-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $297.31 | 2019-2024 | Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $259.92 | 2019-2023 | Symtuza |
| Shionogi INC | $190.25 | 2021-2025 | Fetroja |
| Abbvie INC. | $173.94 | 2022-2025 | |
| Janssen Products, LP | $99.00 | 2021 | |
| Theratechnologies INC. | $91.70 | 2022-2023 | Egrifta, Trogarzo |
| Emd Serono, INC. | $62.31 | 2023-2024 | Serostim |
| Paratek Pharmaceuticals, INC. | $61.70 | 2021-2025 | Nuzyra |
| Allergan, INC. | $46.74 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $42.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.56 | 2021 | |
| Lilly USA, LLC | $30.66 | 2019 | |
| Altathera Pharmaceuticals LLC | $29.11 | 2024 | Sotalol Hydrochloride |
| Kestra Medical Technology Services, INC. | $24.59 | 2025 | Assure Wcd |
| Pfizer INC. | $23.43 | 2021 | |
| Napo Pharmaceuticals INC | $21.40 | 2019 | |
| Amgen INC. | $21.06 | 2023 | Repatha |
| Medicomp INC | $19.67 | 2023 | Telepatch Cardiac Monitor |
| Aimmune Therapeutics, INC. | $17.64 | 2024 | |
| Vyera Pharmaceuticals, LLC | $17.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.93 | 2025 | Rebyota |
| Nabriva Therapeutics, Plc | $13.01 | 2021 | |
| Irhythm Technologies, INC. | $12.24 | 2022 | |
| Leadiant Biosciences, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Khemka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.